- Combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early cancer detection, diagnostic insights, and targeted immunotherapies
- The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to elevate therapeutic efficacy and patient care
- By joining forces, the two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments
- GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development
- Renovaro’s intimate knowledge about vital aspects of the immune system and how cancers could respond to treatment may help strengthen GEDi Cube’s AI technology
Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell, and immunotherapy platforms that modulate immune responses against cancers and infectious diseases, and GEDi Cube International Ltd., an AI medical technology company, recently signed a definitive agreement to combine in a stock-for-stock acquisition (https://ibn.fm/gA9cq).
The combined company brings together renowned leaders across AI and immunotherapy, including Dr. Dybul, who brings decades of global health leadership experience; GEDi Cube CEO Craig Rhodes, the former head of Life Sciences for Europe, the Middle East, and North Africa at…
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
